Oppenheimer Asset Management Inc. Has $5.08 Million Position in Regeneron Pharmaceuticals, Inc. (REGN)
Oppenheimer Asset Management Inc. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,351 shares of the biopharmaceutical company’s stock after buying an additional 340 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $5,084,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Jennison Associates LLC boosted its stake in Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares during the last quarter. Janus Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the last quarter. Wellington Management Group LLP boosted its stake in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its stake in Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares during the last quarter. 67.96% of the stock is owned by institutional investors.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 504.00 on Friday. The firm has a market cap of $53.44 billion, a price-to-earnings ratio of 50.56 and a beta of 1.64. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The stock has a 50 day moving average of $486.42 and a 200 day moving average of $439.67.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current fiscal year.
WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/03/oppenheimer-asset-management-inc-has-5-08-million-position-in-regeneron-pharmaceuticals-inc-regn.html.
REGN has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Vetr cut shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price target for the company. in a report on Monday, May 15th. Piper Jaffray Companies raised their price target on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $493.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $495.59.
In related news, major shareholder Sanofi purchased 166,415 shares of the stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Robert E. Landry sold 427 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $493.43, for a total transaction of $210,694.61. Following the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at $4,489,719.57. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 129,405 shares of company stock worth $61,802,672. Corporate insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.